US · Healthcare · Biotechnology
EPS came in at 0.05 against a street estimate of -0.65 — a beat of 107.7%.
Analysts rate Protagonist Therapeutics Inc a buy (9 buy, 1 hold, 0 sell out of 10) with an average price target of $133.31.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.21% |
| Farallon Capital Management, L.L.C. | 9.87% |
| UBS Group AG | 8.05% |
| RTW INVESTMENTS, LLC | 7.87% |
| Wellington Management Company LLP | 5.60% |
| Vanguard Portfolio Management, LLC | 5.41% |
| State Street Corp | 4.85% |
| HHG PLC | 4.50% |
| Document | Date |
|---|---|
| Board / officer change · Q2 2026 | 2026-06-18 |
| Quarterly report · Q1 2026 | 2026-05-05 |
| Results announced · Q2 2026 | 2026-05-05 |
| Proxy statement · Q2 2026 | 2026-04-28 |
| Annual report FY2025 | 2026-02-25 |
| Results announced · Q1 2026 | 2026-02-25 |
| Reg FD disclosure · Q1 2026 | 2026-01-12 |
| Quarterly report · Q3 2025 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Protagonist Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.